Impact of lack of suppression of glucagon on glucose tolerance in humans.
about
Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the BlockOptimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiencyA K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans.Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy.Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humansPartial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia.Differential contribution of dietary fat and monosaccharide to metabolic syndrome in the common marmoset (Callithrix jacchus)Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and womenAlteration of de novo glucose production contributes to fasting hypoglycaemia in Fyn deficient mice.Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes MellitusCrbpI modulates glucose homeostasis and pancreas 9-cis-retinoic acid concentrations.A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro.Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.Differential circulating concentrations of adipokines, glucagon and adropin in a clinical population of lean, overweight and diabetic cats.A computational systems analysis of factors regulating α cell glucagon secretion.TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes.Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.UCP2 is highly expressed in pancreatic alpha-cells and influences secretion and survival.Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatmentDipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis.The alpha-cell as target for type 2 diabetes therapy.The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.LKB1 and AMPKα1 are required in pancreatic alpha cells for the normal regulation of glucagon secretion and responses to hypoglycemiaDual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.Going with the flow: adaptation of β-cell function to glucose fluxes after bariatric surgery.Mechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in Humans.Impaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans.
P2860
Q26825393-367D3CF0-13DA-4A75-A65E-0F5A129006B6Q30424699-53237909-ED0C-4E48-8AB6-F15CEA91DE32Q33284703-FCBED4CF-65E6-41AE-8456-227408495C32Q34237562-0CDAD738-E625-42D5-8B63-88FB50F10089Q34526962-621FAA0F-9EEA-4B95-9CBD-E7C905623526Q34718921-B0991146-F5A1-4650-9AEC-4771BE8AE290Q34996235-D8CA77F7-24BF-47BD-960E-1C804A0F2ACBQ35043457-7A151029-589F-4AF9-BA01-FBD4C0911FE2Q35060763-87A5F16C-C9E5-4738-BCC5-DAF185AF24F5Q35062439-900E53B1-DBA3-4A1E-8B78-5BE8B713B7F0Q35139983-684BDD83-06F5-48BB-9409-1DD90C3CFFFFQ35237844-4016AEFB-F09F-4F88-AD44-D3972E7CB193Q35673081-A061A2AD-A311-4321-824F-3D8608A4B8EAQ35762651-B87B2496-6A37-4152-949D-3850F796341AQ36334933-B6AE4195-3D78-4832-B8DE-CD34CF2C5EAFQ36394674-59AB2B71-74C9-47F4-BD30-66DAD908DB1CQ36562549-6255B27B-2DAE-4E92-AA7A-E2F6877D86B6Q36842541-8BEFE503-E727-425E-BE9B-0958AD77463EQ36954492-9F003943-0BAA-486C-ABA2-3CCC129668D1Q37022586-3C17B368-2767-427C-B62B-86B70FA3F951Q37022837-F8702A26-C789-4325-B60F-D47A86EA9E86Q37260041-E4CECF4E-6818-4C74-88D0-62BC02D2DD96Q37384053-30A2CAB8-DAD8-4385-8B5E-931A8F4223C7Q37977335-A7837AD8-9055-4DDF-BD2E-8081816CE6FAQ41281439-E3361F91-B5CD-414B-9929-6DD5E779185CQ41885386-22F487DB-A6FF-42B1-AB3E-5E63F2C4D332Q42136958-4198D09C-EF18-4E97-AB6A-0F2D9557A0AAQ42936637-E9B6C157-6EF7-459D-A9CE-5B755E17BCCBQ45941398-C0E63B18-EEAF-4E07-938F-A30E85D9090CQ47360675-1CBBDA0D-F2A7-43CD-A668-C7B55183342C
P2860
Impact of lack of suppression of glucagon on glucose tolerance in humans.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Impact of lack of suppression of glucagon on glucose tolerance in humans.
@en
Impact of lack of suppression of glucagon on glucose tolerance in humans.
@nl
type
label
Impact of lack of suppression of glucagon on glucose tolerance in humans.
@en
Impact of lack of suppression of glucagon on glucose tolerance in humans.
@nl
prefLabel
Impact of lack of suppression of glucagon on glucose tolerance in humans.
@en
Impact of lack of suppression of glucagon on glucose tolerance in humans.
@nl
P2093
P1476
Impact of lack of suppression of glucagon on glucose tolerance in humans.
@en
P2093
P304
P407
P433
P577
1999-08-01T00:00:00Z